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Abstract
Objective To estimate the risk of uterine leiomyosarcoma in patients undergoing gynecological surgery and also to identify 
groups at risk for unrecognized uterine leiomyosarcoma.
Methods A national cohort study was performed evaluating all uterine leiomyosarcoma (ULMS) diagnosed in The Nether-
lands between January 2000 and September 2015. Cases were identified and supplied by the nationwide network and registry 
of histo- and cytopathology in The Netherlands (PALGA). Unexpected and expected ULMS were compared. Approval for 
this study was granted by the Medical Ethics Committee of all participating hospitals and by the review board of PALGA.
Results 262 original cases were included. The overall incidence of ULMS in our study was 0.25% or 1:400 patients. The inci-
dence of unexpected ULMS was 0.12% or 1:865 patients. Preoperatively, a malignancy was unexpected in 46% of the cases 
and expected in 54%. Abnormal uterine bleeding constituted most of the symptoms. 90% of women underwent abdominal 
hysterectomy and/or bilateral salpingo-oophorectomy.
Conclusions Leiomyosarcoma are rare. Women aged 40–50 years with abnormal uterine bleeding are most at risk for 
unexpected ULMS. In contrast, this risk is low in postmenopausal women. ULMS were highly uncommon in women aged 
under 40 years.
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Introduction
The number of laparoscopic procedures has decreased in 
favor of laparotomy, since the Food and Drug Administra-
tions (FDA) decided to discourage power morcellation [1–5] 
This decision was based on the occurrence of unexpected 
uterine (leiomyo)sarcoma during hysterectomy or myomec-
tomy for presumed benign fibroids. It was calculated by the 
FDA that this risk is as high as 1 in 498 for uterine leiomyo-
sarcoma (ULMS) [6]. However, the evidence that formed the 
basis for this calculation has been criticized for its weakness 
and potential bias. For instance, mainly single-center studies 
were used and preoperatively diagnosed malignancies were 
included [7, 8]. Recently, the FDA has updated this risk of 
occult ULMS to 1 in 495 to 1 in 1100 women undergoing 
surgery, using data from more recent studies [9]. Applying 
this notable range to a decision analysis for perioperative 
risk estimations regarding laparoscopic hysterectomy ver-
sus laparotomy, scenarios can be found in favor for both 
approaches [10]. To improve the accuracy of such models 
and thus better inform patients, more data on the actual inci-
dence of (unexpected) ULMS are needed. The primary aim 
of our study was to expand the current data by calculating 
the risk of unexpected ULMS during gynecological proce-
dures in The Netherlands. Secondly, we attempted to identify 
groups at relatively high or low risk for ULMS to enhance 
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the preoperative selection for the proper surgical procedure 
of these patients.
Methods and materials
Approval for this study was granted by the Medical Ethics 
Committee of all participating hospitals and by the review 
board of PALGA.
A national cohort study was performed evaluating all 
patients diagnosed with ULMS in The Netherlands between 
January 2000 and September 2015. Cases were identified 
and supplied by the nationwide network and registry of 
histo- and cytopathology in The Netherlands (PALGA) 
[11]. Women with a histo-pathologically confirmed ULMS 
diagnosis after surgical treatment (abdominal, vaginal and 
laparoscopic hysterectomy; hysteroscopic, laparoscopic and 
abdominal myomectomy; staging laparotomy and debulking 
surgery) were included. Only the initial procedure identify-
ing the ULMS was considered, to avoid multiple registra-
tion of the same case. This naturally implies that second 
opinions of these cases, although registered in the PALGA 
database, were excluded. Basic patient characteristics, rel-
evant medical history, clinical presentation and the preop-
erative diagnostics were retrieved from medical charts. All 
abnormal bleeding patterns (including excessive, irregulair 
or postmenopausal) were defined as abnormal uterine bleed-
ing. Size of myoma was measured in centimeters or com-
pared to weeks of gestation. Rapid growth of myoma was 
considered present if this was explicitly stated in the medical 
charts. Cases were classified as unexpected ULMS if (any 
type of) malignancy was not considered preoperatively, was 
not stated as indication for surgery, or if surgical techniques 
were used that were not in accordance with ULMS treatment 
guidelines (meaning abdominal hysterectomy, with or with-
out salpingo-oophorectomy). Preoperative ultrasound (US), 
computed tomography (CT), magnetic resonance imaging 
(MRI), hysteroscopy and endometrial sampling/curettage 
were considered suspicious if (any type of) malignancy 
was considered by the examining gynecologist, radiologist 
or pathologist. To calculate the risk of ULMS in surgical 
specimens in our cohort, the number of all types of benign 
tumors of the myometrium was used during the same inclu-
sion period. This number was also derived from the PALGA 
database and consisted of leiomyoma (epithelioid, myxoid, 
cellular, bizar, angioleiomyoma, angiomyoleiomoma), 
angiomyofibroblastoma and inflammatory pseudotumors. 
An independent student t test, a Pearson Chi square test and 
Fisher exact test were used where applicable. Differences 
with a p value < 0.05 were considered statistically signifi-
cant. SPSS 20 was used to analyze all data.
To compare our data, a literature search was performed 
using the PubMed, Web of Science, Embase and Cochrane 
databases. Search terms consisted of ‘hysterectomy’, 
‘myomectomy’, ‘uterine (leiomyo)sarcoma’, ‘risk’, ‘preva-
lence’ and ‘incidence’. Only original cohorts from multi-
center studies evaluating ULMS were included to match our 
cohort as well as possible.
Results
From January 2000 until September 2015, 752 ULMS were 
registered in The Netherlands by the PALGA database, orig-
inating from 67 hospitals. 43 hospitals (63%) were willing 
to participate in this study, comprising 6 academic referral 
centers (of 8 in total), 2 additional tertiary referral cent-
ers (of 2), and 35 general hospitals (of 57). These hospitals 
reflect 514 cases (72%). 252 cases were excluded because 
they were not original cases (mainly second opinion referrals 
to specialized pathology centres to confirm the diagnosis) 
or due to not meeting the inclusion criteria (Fig. 1). In all, 
262 original cases were eligible for inclusion of these, the 
medical records were missing from 26 cases and only the 
original pathology report could be found. These cases were, 
therefore, only used to calculate the risk of ULMS and not 
for patient characteristics.
Basic characteristics are shown in Table 1. Of the cases 
of ULMS, 54% were suspected of having a malignancy and 
46% were unexpected. The mean age in the expected group 
was 62 (range 20–91) and it was 52 (range 31–81) in the 
unexpected group. ULMS was most often found in women 
aged 50-60 years as is demonstrated by the age distribu-
tion in Fig. 2. Sixty-seven percent of the unexpected cases 
concerned premenopausal women and 17% of the expected 
cases were premenopausal. Abnormal uterine bleeding 
(AUB) constituted most of the symptoms: 43% overall and 
52% versus 33% in the unexpected and expected group.
The preoperative average uterine size was in accordance 
with 20 weeks of gestation (based on 82 cases) and preop-
erative average myoma size was 10 cm (based on 139 cases). 
Uterus and myoma were larger in the expected ULMS 
group: 19 weeks versus 22 weeks, p 0.01 and 9 cm vs 12 cm, 
p 0.003. For the majority of cases (64%), the myoma was 
solitary (based on 137 cases). In cases with multiple myoma, 
a malignancy was less often expected: 34%, p < 0.06. Rapid 
myoma growth was reported in 67% of cases (based on 42 
cases). No differences were found regarding growth and 
menopausal status or expected versus unexpected ULMS.
Next, the preoperative workup and treatment are pre-
sented. Nearly, all patients (99%) received an US. CT and 
MRI were performed in 29% and 7% of cases, respectively, 
hysteroscopy in 16% and sampling of the endometrium in 
38%. For US, CT, MRI, hysteroscopy and sampling, respec-
tively, 37, 75, 56, 32 and 45% of the findings were indica-
tive of a malignancy (Table 2). US and sampling were more 
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often suspicious in postmenopausal patients than in premen-
opausal patients (51% versus 20%, p < 0.001 and 58% versus 
17%, p < 0.001, respectively).
Most women (69%) were treated by abdominal hyster-
ectomy with or without bilateral salpingo-oophorectomy 
(AH ± BSO). An additional 15% of women received stag-
ing laparotomy or debulking surgery. Laparoscopic hyster-
ectomy (LH) was used in only in 4% of all women. In the 
unexpected group, power morcellation was used in 2 cases. 
In addition, manual morcellation was performed in 2 other 
cases: to accommodate vaginal extraction of the uterus after 
LH, and during conversion of vaginal hysterectomy (VH) 
to AH.
During the same inclusion period as our cohort, 144.431 
benign tumors of the myometrium were registered by PALGA. 
Consequently, the overall incidence of ULMS in our study was 
0.25% or 1:400 patients. The risk of unexpected ULMS was 
0.12% or 1:865 patients. The risk of receiving other treatment 
for ULMS than AH ± BSO or staging/debulking in the unex-
pected group was 0.04% or 1:2500 patients.
Discussion
This nationwide cohort study evaluated all ULMS cases in 
The Netherlands from January 2000–September 2015. The 
risk of encountering an unexpected ULMS was 0.12% or 
25 hospitals did not parcipate 
165 second opinions
87 not meeng inclusion criteria
752 cases
262 cases
514 cases
349 cases
Fig. 1  Inclusion flowchart. 25 hospitals did not participate in the 
majority of instances without reason. Second opinions consisted of 
double registrations in the PALGA system. Only the first original 
case was included in this study. Not meeting inclusion criteria: 14 
stromal tumors of unknown significance (STUMP), 5 endometrial 
stromal sarcoma (ESS), 4 carcinosarcoma, 2 adenosarcoma, 1 malig-
nant mixed müllarian tumor, 1 undifferentiated endometrial carci-
noma, 2 cellular leiomyoma, 43 other reasons (non-gynecological 
sarcomatoid tumors or recurrences of primary tumors not eligible for 
inclusion), and from 15 cases no chart could be found
Table 1  Basic characteristics
Age: mean (standard deviation, range); expected/symptoms/type of 
surgery: percentages. Rapid myoma growth based on 42 cases
AUB abnormal uterine bleeding, AH abdominal hysterectomy, BSO 
bilateral salpingo-oophorectomy, LH laparoscopic hysterectomy, VH 
vaginal hysterectomy, MM myomectomy, TCRM transcervical resec-
tion of myoma
*Significant at p ≤ 0.05
a Uterine size based on 82 cases
b Myoma size based on 139 cases
Cohort Unexpected Expected
N 236 109 (46%) 127 (54%)
Age 58 (12, 20–91) 52 (9, 31–81)* 62 (12, 20–91)*
Menopause
 Pre 40 67* 17*
 Post 60 33* 83*
Symptoms
 Pain 15 14 16
 AUB 43 52 33
 AUB + pain 12 12 12
 Mass effect 21 20 22
 Weight loss 8 0 15
 None 2 2 2
Type of surgery
 AH 25 46 5
 AH + BSO 46 30 65
 LH 4 7 2
 VH 1 3 0
 MM 2 4 0
 TCRM 4 7 1
 Debulking 13 1 26
 Other 5 3 1
No of myoma
 One 64 57 72
 > One 36 43 28
 Uterine  sizea 20 19* 22*
 Myoma  sizeb 10 9* 12*
Rapid myoma growth
 No 33 44 18
 Yes 67 56 82
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1:865 patients. Moreover, the risk for patients with ULMS 
to undergo surgical treatment other than AH ± BSO, staging 
or debulking was 0.04% or 1:2500 patients. These numbers 
are in concurrence with the studies found in our literature 
search. In total, 7 multicenter cohorts were found with inci-
dences ranging from 2.3% or 1:44 to 0.07% or 1:1465 cases 
[12–18] (Table 3). Unfortunately, a meta-analysis of the data 
from these studies could not be performed due to heteroge-
neity of the included study population.
Based on our evaluation, certain groups are at higher risk 
for preoperatively unrecognized ULMS than others. First, 
women aged 40 years and younger constituted only 4% of 
our cohort. Therefore, minimally invasive and/or fertility 
sparing treatments such as a laparoscopic myomectomy 
could be considered for these women. The highest risk for 
preoperatively unrecognized ULMS was found in women 
aged 40–50. In this age group, a malignancy was suspected 
in only 15% of the women as opposed to 53% and 63% in 
women aged 50–60 and 60–70, respectively. In women over 
70 years of age, a malignancy was suspected in over 80%. 
Furthermore, symptoms and preoperative workup were not 
distinctive for this high-risk group. In our cohort, most pre-
menopausal women complained of AUB and, in contrast 
to postmenopausal women, this usually does not indicate 
a malignancy. Furthermore, as AUB and fibroids are the 
main indication for hysterectomy in benign conditions, these 
women are likely to undergo surgery [19].
Next, a significant difference was found between uterus 
size and myoma size in unexpected and expected cases. Yet, 
these differences were small and size was overall large in 
both groups. Furthermore, these results should be inter-
preted with caution because possibly only distinctive cases 
were well registered.
Finally, it was found that preoperative diagnostics were 
less likely to diagnose a malignancy in our cohort of pre-
menopausal women. For instance, endometrial sampling 
demonstrated a malignancy in 57% of postmenopausal 
women compared to only in 17% of premenopausal women. 
Although US is often a readily available diagnostic test, 
the diagnostic value in our cohort was low. Interestingly, 
an evaluation of tumor vascularity and Doppler measure-
ments was not performed but in a few cases, although this 
could be due to suboptimal reporting and due to the time 
span of the cohort. These measurements should not be over-
looked as meanwhile favorable numbers regarding sensitiv-
ity, specificity and positive predictive value for ULMS have 
been described [20]. The vast majority of CT imaging (89%) 
was reserved for women over 50 years of age. Naturally, 
in this group malignancies were more often suspected and 
CT was used to confirm the suspicion raised by a patients 
history, or to aid in staging of the disease. However, in light 
of the aforementioned risk group it is interesting to notice 
that in women aged 40–50, a CT and MRI was performed 
in a minority of cases. One explanation may be that these 
women were previously not considered at risk for ULMS. 
An increased awareness may thus aid in reducing the number 
of unexpected ULMS in this group.
Our study has some potential weaknesses. Not all insti-
tutes were willing to participate; therefore, not all cases 
could be verified. Next, due to the retrospective design, miss-
ing data occurred. A surprisingly low number of patients 
were treated by minimally invasive surgical treatments, 
explaining the very low risk for patients with unexpected 
ULMS to undergo non-standard oncological treatments. 
Therefore, this risk (1:2500) may have limited external 
validity. The strength of our study is the nationwide cohort. 
Almost all tertiary care academic centers as well as the 
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Fig. 2  Age distribution of our cohort (%)
Table 2  Preoperative diagnostic workup
Numbers are percentages of the cohort
*Significant at p ≤ 0.05
Cohort 
(N = 236)
Premenopausal Postmen-
opausal
Ultrasound
 Total 99 98 99
 Suspicious 37 20* 51*
CT
 Total 29 19 36
 Suspicious 75 71 76
MRI
 Total 7 7 7
 Suspicious 56 43 67
Hysteroscopy
 Total 16 13 29
 Suspicious 32 18 39
Endometrial Sampling
 Total 38 32 44
 Suspicious 45 17* 57*
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majority of general care hospitals in The Netherlands par-
ticipated in this study. In our literature search, only 1 other 
study encompasses true nationwide data [12]. This study 
consisted of women undergoing laparoscopy for abnormal 
uterine bleeding or leiomyoma. Our study evaluated all 
ULMS cases, eliminating selection bias due to treatment 
groups. Therefore, notwithstanding the shortcomings, our 
data are a valuable addition to the already existing evidence. 
Furthermore, our study identified high- and low-risk groups, 
thereby offering an additional means in clinical practice to 
decide a treatment strategy together with the patient. Future 
studies will include a matched case–control study using this 
cohort, to further define risk factors for ULMS. However, 
finding proper matched cases will be challenging. Also, 
given the increase in laparoscopic procedures in the past 
decade it will be of interest to analyze a more recent cohort 
to compare the number of expected versus unexpected cases 
and the number of patients who received suboptimal surgi-
cal treatment.
Conclusion
The risk of ULMS is overall low and the majority of cases 
were expected. Women aged 40–50 years with AUB are 
most at risk for unexpected malignancies. ULMS was highly 
uncommon in women aged under 40 years.
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